Spark Therapeutics posts $65 million quarterly loss

Spark Therapeutics reported a net loss of $65 million, or $1.90 per share, for the third quarter of 2017 compared with a net loss of $32.6 million, or $1.07 per share, for the same period of 2016.

Revenue rose from $1.3 million in 2016’s third quarter to $1.9 million in 2017’s third quarter, according to a press release.

Research and development costs rose from $22.4 million a year ago to $39.3 million.

General and administrative expenses were $26.6 million compared with $12 million in 2016, an increase attributed to a rise in salaries and related costs due to an increased headcount, as well as costs related to launch preparation activities for Luxturna (voretigene neparvovec), the company’s inherited retinal disease treatment.

Spark Therapeutics reported a net loss of $65 million, or $1.90 per share, for the third quarter of 2017 compared with a net loss of $32.6 million, or $1.07 per share, for the same period of 2016.

Revenue rose from $1.3 million in 2016’s third quarter to $1.9 million in 2017’s third quarter, according to a press release.

Research and development costs rose from $22.4 million a year ago to $39.3 million.

General and administrative expenses were $26.6 million compared with $12 million in 2016, an increase attributed to a rise in salaries and related costs due to an increased headcount, as well as costs related to launch preparation activities for Luxturna (voretigene neparvovec), the company’s inherited retinal disease treatment.